Boehringer Ingelheim Dealt New Blow In Nearly Two Years Of Review For Pradaxa In Australia
This article was originally published in The Pink Sheet Daily
Executive Summary
Australia’s Health Ministry calls for additional study of anticoagulant Pradaxa, dealing a fresh blow to Boehringer Ingelheim’s hopes of getting listed on the national reimbursement program nearly two years after initial regulatory approval.